Investigating porcine and feline zona pellucida as immunocontraceptive antigens in the female domestic cat by Eade, Jocye A.
 
 
 
 
 
 
 
 
Investigating porcine and feline zona pellucida as 
immunocontraceptive antigens in the female domestic cat  
 
 
 
 
 
 
 
Joyce A. Eade, BSc (Hons) 
This thesis is presented for the degree of Doctor of Philosophy at Murdoch University 
2007  ii
 
 
 
 
 
 
 
 
DECLARATION 
 
I declare that this thesis is my own account of my research and contains as its main 
content work which has not previously been submitted for a degree at any tertiary 
education institution. 
 
 
…………………………………………………………….. 
Joyce A. Eade  iii
ABSTRACT 
 
Immunocontraception, or contraception mediated by the immune system, is being 
widely studied as an alternative, humane form of population control.  The induction of 
an immune response against a specific component of the mammalian oocyte, termed 
zona pellucida (ZP) has been shown to be an effective immunocontraceptive in several 
species.  Comparatively little work has been done investigating the use of ZP antigens 
in the domestic cat.  This study aimed to investigate porcine ZP(B+C) and feline ZPA, 
B and C as immunogens in the domestic cat, and further to elucidate their effects on 
reproduction.  Immunisation of female cats with porcine ZP(B+C) failed to elicit a 
detectable antibody response as assessed by ELISA, immunoblotting and 
immunohistochemistry.  Additionally, there was no effect on the structure of the ovaries 
nor on breeding performance.  Feline ZPA, B and C were cloned into the 
pkCMVint.polyli mammalian expression vector and used to immunise female cats.   
ELISA revealed that immunisation with either pkCMVint.fZP(B+C) or pkCMVint.fZPA 
DNA (Treated) resulted in a low-level circulating antibody response, which was 
apparently short-lived.   Immunoblotting did not reveal any common pattern of 
recognition of antigenic polypeptides between responding animals.  Ovaries from fZP 
Treated animals, however, showed antibody binding specifically on the ZP of follicles 
from late primary / early secondary, through to antral stages.  Despite the antibody 
binding, the overall structure of the ovaries remained unaffected in all but two of the 
fZP Treated cats.  Two fZPA immunised cats exhibited ovaries that had no 
recognisable follicular structures, however, the observed abnormalities could not be 
conclusively linked to fZPA immunisation.   Overall, a significant lymphoproliferative 
response was shown in fZP Treated cats when compared with Controls.  Fertility was 
not significantly affected in fZP Treated cats, although there was a tendency towards 
increased incidence of unsuccessful matings or pregnancies.  The fZP DNA 
preparations studied here exhibit potential as an immunocontraceptive, with the ability   iv
to generate a lymphoproliferative response against fZP and elicit antibodies 
specifically recognizing fZP in situ.  Further studies should continue to investigate the 
immunogenicity of, and characterise the immune response against, such fZP DNA 
preparations.   
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